Anti-tumoral properties of endogenous angiogenesis inhibitors: A case for continued TIMP-2 preclinical development

Current Angiogenesis

Volumn 1, Issue 2, 2012, Pages 148-156

  Stetler Stevenson, William G ^a   Bourboulia, Dimitra ^a   Guedez, Liliana ^a   Jensen Taubman, Sandra ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenic therapy; Endogenous angiogenesis inhibitor; Tumor growth inhibition

Indexed keywords

CEDIRANIB; FIBROBLAST GROWTH FACTOR 2; FIBULIN 5; INTERLEUKIN 6; PROTEIN TYROSINE PHOSPHATASE SHP 1; SOMATOMEDIN C RECEPTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMSTATIN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CYTOKINE RELEASE; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84875775160     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201020148     Document Type: Article

References (65)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-257.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6(4): 273-286.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353-364.
4. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17(11): 1359-1370.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2(10): 727-739.
6. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004; 112(7-8): 496-507.
7. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-285.
8. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999; 96(26): 14888-14593.
9. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999; 103(6 Pt 1): 1145-1149.
10. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79(2): 315-328.
11. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390(6658): 404-407.
12. Belotti D, Foglieni C, Resovi A, Giavazzi R, Taraboletti G. Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol 2011; 43(12): 1674-1685.
13. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295(5552): 140-143.
14. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003; 3(6): 589-601.
15. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003; 100(8): 4766-4771.
16. Gerstner E. Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma. 2012 [cited 2012 January 7, 2012]; Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid=654715&version=HealthProfessional&protocolsearchid=10105616.
17. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6(1): 1-12.
18. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65(10): 3967-3979.
19. Xie L, Duncan MB, Pahler J, et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci USA 2011; 108(24): 9939-9944.
20. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115(Pt 19): 3719-3727.
21. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803(1): 55-71.
22. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11(2): 143-152.
23. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20(3): 161-168.
24. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008; 1(27): re6.
25. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2(10): 737-74.
26. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase Adeficient mice. Cancer Res 1998; 58(5): 1048-1051.
27. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103(3): 481-490.
28. Fernandez CA, Moses MA. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun 2006; 345(1): 523-529.
29. Ikenaka Y, Yoshiji H, Kuriyama S, et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003; 105(3): 340-346.
30. Reed MJ, Koike T, Sadoun E, Sage EH, Puolakkainen P. Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. Microvasc Res 2003; 65(1): 9-17.
31. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler- Stevenson M, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158(4): 1207-1215.
32. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Investig 1998; 102(11): 2002-2010.
33. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25(17): 3934-3942.
34. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9(4): 407-415.
35. Kang KH, Park SY, Rho SB, Lee JH. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc Res 2008; 79(1): 150-160.
36. Clarke M, Mitchell KW, Goodship J, et al. Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism. Br J Ophthalmol 2001; 85(12): 1429-1431.
37. Barbazetto IA, Hayashi M, Klais CM, Yannuzzi LA, Allikmets R. A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol 2005; 123(4): 542-543.
38. Hernandez-Barrantes S, Toth M, Bernardo MM, et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1- MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 2000; 275(16): 12080-12089.
39. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270(10): 5331-5338.
40. Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563(1-3): 129-134.
41. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264(29): 17374-17378.
42. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248(4961): 1408-1410.
43. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157(2): 351-358.
44. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114(2): 171-180.
45. Seo DW, Li H, Qu CK, et al. Shp-1 mediates the antiproliferativeactivity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006; 281(6): 3711-3721.
46. Goyal A, Pal N, Concannon M, et al. Endorepellin, perlecan angiostatic module, interacts with both the [alpha]2[beta]1 integrin and VEGFreceptor 2: A dual receptor antagonism. J Biol Chem 2011; 286(29): 25947-25962.
47. Nystrom A, Shaik ZP, Gullberg D, et al. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009; 114(23): 4897-4806.
48. Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 2006; 25(30): 4230-4234.
49. Oh J, Seo DW, Diaz T, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004; 64(24): 9062-9069.
50. Seo DW, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG. An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and antitumorigenic activity in vivo. Peptides 2011; 32(9): 1840-1848.
51. Guedez L, Rivera AM, Salloum R, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003; 162(5): 1431-1439.
52. Fernandez CA, Roy R, Lee S, et al. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem 2010; 285(53): 41886-41895.
53. Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998; 17(17): 5238-5248.
54. Maskos K, Lang R, Tschesche H, Bode W. Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2. J Mol Biol 2007; 366(4): 1222-1231.
55. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002; 8(10): 3259-3269.
56. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxiainducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003; 163(3): 1001-1011.
57. Lahat N, Bitterman H, Engelmayer-Goren M, Rosenzweig D, Weiss-Cerem L, Rahat MA. Reduced TIMP-2 in hypoxia enhances angiogenesis. Am J Physiol Cell Physiol 2011; 300(3): C557-C566.
58. Bourboulia D, Jensen-Taubman S, Rittler MR, et al. Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor Microenvironment. Am J Pathol 2011; 179(5): 2589-2600.
59. Walsh LA, Cepeda MA, Damhanovski S. Analysis of the MMPdependent and independent functions of tissue inhibitor of mealloprotienase-2 on the invasiveness of brest cancer cells. J Cell Commun Signal [Internet]. 2012 1/10/12; 6(6):[http://www.springerlink.com/content/k8116w201445658q/fulltext.htmlp.
60. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29(6): 1096-1107.
61. Zheng D, Kurenova E, Ucar D, et al. Targeting of the protein interaction site between FAK and IGF-1R. Biochem Biophys Res Commun 2009; 388(2): 301-305.
62. Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180(1): 12-16.
63. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46(7): 1223-1231.
64. Jaworski DM, Soloway P, Caterina J, Falls WA. Tissue inhibitor of metalloproteinase-2(TIMP-2)-deficient mice display motor deficits. J Neurobiol 2006; 66(1): 82-94.
65. Larsen MB, Stephens RW, Brunner N, et al. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients. Scand J Immunol 2005; 61(5): 449-460.